Sonnet BioTherapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

DISCLOSURES ABOUT FAIR VALUE (Details)

DISCLOSURES ABOUT FAIR VALUE (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Assets:
Available-for-sale securities	$ 12,062	$ 56,949
Liabilities:
Derivative liability	2,341,500	0
Fair Value, Inputs, Level 1 [Member]
Assets:
Available-for-sale securities	10,562	55,449
Liabilities:
Derivative liability	0
Fair Value, Inputs, Level 2 [Member]
Assets:
Available-for-sale securities	1,500	1,500
Liabilities:
Derivative liability	0
Fair Value, Inputs, Level 3 [Member]
Assets:
Available-for-sale securities	0	0
Liabilities:
Derivative liability	$ 2,341,500

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References + Details